全文获取类型
收费全文 | 9017篇 |
免费 | 586篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 190篇 |
儿科学 | 156篇 |
妇产科学 | 146篇 |
基础医学 | 1484篇 |
口腔科学 | 140篇 |
临床医学 | 729篇 |
内科学 | 1613篇 |
皮肤病学 | 276篇 |
神经病学 | 956篇 |
特种医学 | 559篇 |
外科学 | 1443篇 |
综合类 | 34篇 |
一般理论 | 3篇 |
预防医学 | 316篇 |
眼科学 | 252篇 |
药学 | 601篇 |
中国医学 | 15篇 |
肿瘤学 | 732篇 |
出版年
2023年 | 70篇 |
2022年 | 95篇 |
2021年 | 188篇 |
2020年 | 144篇 |
2019年 | 185篇 |
2018年 | 199篇 |
2017年 | 174篇 |
2016年 | 233篇 |
2015年 | 279篇 |
2014年 | 319篇 |
2013年 | 413篇 |
2012年 | 576篇 |
2011年 | 614篇 |
2010年 | 350篇 |
2009年 | 340篇 |
2008年 | 515篇 |
2007年 | 565篇 |
2006年 | 545篇 |
2005年 | 570篇 |
2004年 | 499篇 |
2003年 | 451篇 |
2002年 | 365篇 |
2001年 | 140篇 |
2000年 | 139篇 |
1999年 | 124篇 |
1998年 | 80篇 |
1997年 | 56篇 |
1996年 | 64篇 |
1995年 | 62篇 |
1994年 | 56篇 |
1993年 | 46篇 |
1992年 | 65篇 |
1991年 | 84篇 |
1990年 | 77篇 |
1989年 | 65篇 |
1988年 | 60篇 |
1987年 | 86篇 |
1986年 | 82篇 |
1985年 | 68篇 |
1984年 | 55篇 |
1983年 | 58篇 |
1982年 | 33篇 |
1981年 | 33篇 |
1980年 | 26篇 |
1979年 | 49篇 |
1978年 | 39篇 |
1976年 | 35篇 |
1975年 | 29篇 |
1974年 | 30篇 |
1973年 | 29篇 |
排序方式: 共有9645条查询结果,搜索用时 78 毫秒
101.
Muhammad Daud Prasad Dasari Marion Adelfinger Daniela Langenhorst Jasmin Lother Dragana Slavkovic-Lukic Carsten Berges Michaela Kruhm Annette Galler Cathrin Schleussner Christian H. Luther Karl Alberter Anton Althammer Haroon Shaikh Niklas Pallmann Jochen Bodem Mohammed El-Mowafy Andreas Beilhack Marcus Dittrich Max S. Topp Peter F. Zipfel Niklas Beyersdorf 《European journal of immunology》2023,53(11):2250284
To obtain a better understanding of the biology behind life-threatening fungal infections caused by Candida albicans, we recently conducted an in silico screening for fungal and host protein interaction partners. We report here that the extracellular domain of human CD4 binds to the moonlighting protein enolase 1 (Eno1) of C. albicans as predicted bioinformatically. By using different anti-CD4 monoclonal antibodies, we determined that C. albicans Eno1 (CaEno1) primarily binds to the extracellular domain 3 of CD4. Functionally, we observed that CaEno1 binding to CD4 activated lymphocyte-specific protein tyrosine kinase (LCK), which was also the case for anti-CD4 monoclonal antibodies tested in parallel. CaEno1 binding to naïve human CD4+ T cells skewed cytokine secretion toward a Th2 profile indicative of poor fungal control. Moreover, CaEno1 inhibited human memory CD4+ T-cell recall responses. Therapeutically, CD4+ T cells transduced with a p41/Crf1-specific T-cell receptor developed for adoptive T-cell therapy were not inhibited by CaEno1 in vitro. Together, the interaction of human CD4+ T cells with CaEno1 modulated host CD4+ T-cell responses in favor of the fungus. Thus, CaEno1 mediates not only immune evasion through its interference with complement regulators but also through the direct modulation of CD4+ T-cell responses. 相似文献
102.
Henrik S. Thomsen 《Basic & clinical pharmacology & toxicology》1997,80(2):108-110
Abstract: The effect of a standardized verbal interview on the frequency of reported adverse events to an intravenous injection of a non-ionic low-osmolar magnetic resonance (MR) contrast medium was studied during a low noise (low anxiety) magnetic resonance imaging (MRI) examination. During a 26-month period 863 patients had an intravenous bolus (<10 sec.) injection of either 0.1 mmol/kg b.wt. or 0.3 mmol/kg b.wt. gadodiamide, were examined in 0.1 Tesla (T) MRI unit. All patients received written information about the examination, but no specific information about possible adverse events to the contrast medium. During the first 15 months, 479 patients were asked after the examination by the same radiographer the following question "Did you feel anything in relation to or after the contrast medium injection?". If the answer was affirmative, the patient was asked to specify the experience. During the subsequent 11-month period, 384 patients had no interview about whether they felt anything in relation to the contrast medium injection. Only 9 out of 863 patients reported an adverse event and they all belonged to the group, which was interviewed. In 8 cases the adverse events lasted less than 5 min. The ninth patient had an attack of migraine 20 min. after the injection of the contrast medium. In one of the patients, who experiencied nausea, it was necessary to postpone scanning for 2 min. Two of the 9 adverse events were considered to be unrelated to the contrast medium. None of the 121 patients receiving the triple dose reported an adverse event. The frequency of reported adverse events depends on whether this information is obtained by active questioning. All reported adverse events were clinically mild and no dose-response effect was observed. 相似文献
103.
Preben Jakobsen Bente Søresen Lars Bastholt Mansoor Raza Mirza Susanne B. Gjedde Henning T. Mouridsen Carsten Rose 《Cancer chemotherapy and pharmacology》1994,35(1):45-52
A high-pressure liquid chromatographic method for determination of the bisdioxopiperazine derivative ADR-529 (ICRF-187), a compound proven effective in protection against anthracycline-induced cardiotoxicity, has been developed. The limit of quantitation was 5 ng/ml using a narrow-bore 5-m silica column and UV detection. The method was used for determination of pharmacokinetic profiles of ADR-529 after a 3-weekly i.v. administration of different doses of ADR-529 (600–1000 mg/m2) together with different doses of epirubicin (E, 60–100 mg/m2), fixed-dose cyclophosphamide (C, 600 mg/m2), fixed-dose 5-fluorouracil (F, 600 mg/m2), and daily administration of tamoxifen (T, 30 mg; CEF-T) in the treatment of patients with metastatic breast cancer. Pharmacokinetic parameters for epirubicin were also determined. The aim of the study was to determine (1) whether the pharmacokinetics of ADR-529 as part of a combination with CEF-T changes with increasing doses of ADR-529 and increasing doses of epirubicin and (2) whether the pharmacokinetics of epirubicin in the same combinations is altered with the administration of increasing doses of ADR-529. A total of 82 patients were included. A crossover study including 16 of the patients showed no significant difference in epirubicin pharmacokinetic parameters when epirubicin was given with or without concomitant administration of ADR-529. Apart from minor changes in the distributional half-lives, the pharmacokinetic parameters of epirubicin were not altered with increasing doses of ADR-529, nor were the pharmacokinetic parameters of ADR-529 itself. Escalating doses of epirubicin did not significantly alter the pharmacokinetic parameters of ADR-529 with the exception of a 30% increase in the terminal half-life and a decrease in total body clearance when the epirubicin dose was raised from 60 to 100 mg/m2. We conclude that concomitant administration of ADR-529 does not alter the distribution and elimination of epirubicin in doses suitable for preventing the anthracycline-induced cardiotoxicity. 相似文献
104.
Friedrich Weber Carsten Kremer Mario Klinkhammer Bettina Rasier Mario Brock 《Journal of neuro-oncology》1994,18(3):217-224
Summary This publication describes a new model to investigate the influence of tumor necrosis factor- (TNF-) on a three-dimensional glial cell aggregate under defined, standardized, reproducible conditions using the glioma cell line A 172.The cells are initially grown as normal monolayer culture until they reach a cell density of up to 1×106. Subsequently they are grown as spheroids by the liquid overlay technique. Spheroids grown in this way were divided into ten groups of more than 50 cell aggregates. Three groups were coincubated with free TNF- in increasing dosages (100 ng/ml, 200 ng/ml and 1000 ng/ml); three groups were incubated with empty liposomes (0.2 mg/ml, 0.4 mg/ml and 2 mg/ml); three groups received liposomes which had been loaded with TNF-, and one group, which received no treatment, served as control.The diameter of the spheroids ranged from 80 m to 350 m. There was no significant difference in growth between the 3 groups treated with free TNF-. Comparing spheroids treated with TNF- with those which had been coincubated with empty liposomes, there was a significant difference (p<0.001) in growth, which correlated with the amount of liposomes. Similarly, free TNF- had a significantly (P<0.001) stronger growth-inhibiting effect as compared to liposomes loaded with TNF-. Comparing the groups treated with liposomes only to those treated with liposomes loaded with TNF-, the latter exhibited a more marked (although not significantly) growth-inhibiting effect.The preliminary conclusion is that the major growth-inhibiting effect seems to be mediated by the liposomes. This phenomenon is in agreement with results obtained in monolayer cultures. 相似文献
105.
Bruce C. Baguley Gail Cole Lindy L. Thomsen Li Zhuang 《Cancer chemotherapy and pharmacology》1994,33(1):77-81
The relationship of serotonin (5-HT) receptors to the action of the experimental antitumour drugs flavone-8-acetic acid (FAA) and 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA) was studied. Both FAA and 5,6-MeXAA are known to induce the synthesis of tumour necrosis factor- (TNF) and to stimulate nitric oxide synthesis in vivo, as measured by elevation of plasma nitrate. Serotonin potentiated the effect of a subtherapeutic dose of 5,6-MeXAA (20 mg/kg) as measured both by plasma nitrate increase and by growth delay of s.c. implanted colon 38 tumours. On the other hand, administration of the serotonin 5-hydroxytryptamine-2 (T-HT2) antagonist cyproheptadine (20 mg/kg) inhibited both the plasma nitrate response and, to a lesser extent, the induction of tumour haemorrhagic necrosis by 5,6-MeXAA, FAA and TNF. Reduction of circulating plasma serotonin by pre-treatment withp-chlorophenylalanine and reserpine reduced the plasma nitrate response, but not the tumour necrosis response, to 5,6-MeXAA (30 mg/kg). It is suggested that serotonin is necessary for the induction of nitric oxide synthases and acts, either directly or indirectly, in concert with TNF. Serotonin agonists may have utility in increasing nitric oxide synthesis in response to TNF or to agents that induced TNF as part of their antitumour action.This research was supported by the Auckland Division of Cancer Society of New Zealand and the Health Research Council of New Zealand, by the Health Research Council of New Zealand and by the Ruth Spencer Medical Research Fellowship Trust. 相似文献
106.
L. L. Thomsen H. K. Iversen C. Emmeluth P. Bie 《European journal of clinical pharmacology》1995,48(2):139-142
Endothelin-1 and nitric oxide play an important regulatory role in the control of vascular smooth muscle tone. Nitroglycerin (NTG), a nitric oxide donating drug, may inhibit endothelin production. In this double-blind placebo-controlled crossover study, plasma levels of endothelin-1 were measured before and immediately (5–30 s) after 80 min infusion of NTG (glyceryl trinitrate) or saline in 12 healthy subjects. On two different days separated by at least 1 week, NTG in four different doses, 0.015, 0.25, 1.0, and 2.0 g·kg–1·min–1, or placebo (isotonic saline) was infused successively for 20 min each dose. During the infusion blood pressure and heart rate were measured. NTG infusion significantly decreased systolic blood pressure from 112.4 to 103.4 mmHg and pulse pressure from 39.3 to 29.5 mmHg. Heart rate increased from 62.7 to 73.1 beats·min–1. No changes in endothelin-1 plasma levels were induced by NTG infusion (2.4 pg·ml–1 before NTG vs. 2.7 pg·ml–1 after NTG) and placebo infusion also did not affect plasma endothelin-1. It is concluded that venous plasma levels of endothelin-1 are not altered immediately after NTG infusion. 相似文献
107.
V Wijendran R B Bendel S C Couch E H Philipson K Thomsen X Zhang C J Lammi-Keefe 《The American journal of clinical nutrition》1999,70(1):53-61
BACKGROUND: The fatty acids arachidonic acid (AA; 20:4n-6) and docosahexaenoic acid (DHA; 22:6n-3) are essential for fetal growth and development, but their metabolism may be altered in insulin resistance. OBJECTIVES: The objectives were to determine maternal plasma phospholipid polyunsaturated fatty acid concentrations in pregnant women receiving dietary therapy for gestational diabetes mellitus (GDM) and to identify maternal factors associated with plasma phospholipid AA and DHA concentrations in the third trimester. DESIGN: Fasting plasma phospholipid fatty acids were determined in women with GDM (n = 15) receiving dietary therapy only and in healthy, pregnant women without GDM (control group, n = 15) at 27-30, 33-35, and 36-39 wk gestation. RESULTS: Maternal plasma phospholipid (as % by wt of total fatty acids and mg/L) linoleic acid (18:2n-6), AA, and 22:5n-6 concentrations did not differ significantly between women with GDM and control subjects. The other n-6 long-chain polyunsaturated fatty acids (% by wt) were lower in GDM subjects than in control subjects. Plasma phospholipid (expressed as % by wt and mg/L) linolenic acid (18:3n-3) and summed precursors of DHA were lower and DHA (% by wt and mg/L), adjusted for dietary DHA intake, was 13% higher in GDM subjects than in control subjects. Maternal blood hemoglobin A1C was inversely related to plasma phospholipid AA (% by wt) (r = -0.56, P = 0.03) in control subjects and positively associated with plasma phospholipid AA (% by wt) in women with GDM (r = 0.76, P = 0.001). Pregravid body mass index was negatively associated with plasma phospholipid DHA (% by wt) in control subjects (r = -0.55, P = 0.04) and in women with GDM with a body mass index (in kg/m2) <30 (r = -0.76, P = 0.007). CONCLUSIONS: This is the first report documenting alterations in maternal plasma phospholipid PUFAs in pregnant women receiving dietary therapy for GDM. In pregnant woman, both with and without GDM, maternal glycemic control and pregravid BMI appear to be significant predictors of plasma phospholipid AA and DHA, respectively, during the third trimester. Additionally, dietary DHA significantly affects phospholipid DHA concentrations. 相似文献
108.
C G Carsten J R Elmore D P Franklin D D Thomas F Mordan G C Wood 《American journal of surgery》1999,178(2):173-176
BACKGROUND: Although the efficacy of carotid endarterectomy for asymptomatic carotid stenosis has been established, no cost-effective approach for identification of these patients has yet been devised. The purpose of this study was to develop a limited carotid duplex screening examination to be utilized for the detection of asymptomatic carotid stenoses. METHODS: Carotid screening examinations employed rapid identification of the carotid bifurcation using color-flow duplex imaging and an immediate Doppler-derived velocity of the segment of the internal carotid artery with the most turbulent flow. Complete examinations were then finished using well-established protocols in our accredited vascular laboratory. A total of 512 patients were referred for complete studies based upon standard indications. Criteria for at least a 50% internal carotid artery stenosis on the complete examination was defined as a peak systolic velocity (PSV) of at least 125 cm/sec. Receiver operator characteristic (ROC) curves were then constructed to identify the optimal screening velocity criteria as compared with the final results on the complete examination. RESULTS: Five screening examinations were technically limited yielding a total of 507 patients with 1,014 carotid arteries available for analysis. Comparison of screening examinations versus complete examinations for a PSV of 125 cm/sec yielded sensitivity 86%, specificity 98%, positive predictive value (PPV) 95%, and a negative predictive value (NPV) 93%. ROC analysis identified a "cut point" of 115 cm/sec on the screening examinations to achieve sensitivity 91%, specificity 95%, PPV 89%, and NPV 96%. Time to perform screening examinations averaged 3.2 minutes per patient. Three patients had common carotid lesions not identified on the limited internal carotid screening examinations. CONCLUSIONS: Screening carotid examinations are a rapid, reliable, and relatively inexpensive method for detection of patients with asymptomatic internal carotid artery stenosis. Limited screening examinations should be developed in each vascular laboratory and utilized in high-risk patients. 相似文献
109.
p
< 0.05). On postoperative
days 3 and 7 the values were 7.2 (5.3–8.2) and 7.5 (5.4–9.4) mmol/L,
respectively, in the erythropoietin group compared to 6.7 (5.2–7.8)
and 6.9 (5.1–8.6) mmol/L in the placebo group (
p
<
0.01). At discharge the hemoglobin concentration was 7.8 (5.9–8.8)
mmol/L in the erythropoietin group and 7.2 (5.4–8.6) mmol/L in the
placebo group (
p
< 0.002). The blood loss during
operation was similar in the two groups. In the erythropoietin group
the median value was 280 ml (range 25–2000 ml), with the lower and
upper quartiles 150 and 500 ml, respectively. In the placebo group the
blood loss was median 300 ml (range 50–1800 ml), with the lower and
upper quartiles 200 and 750 ml, respectively. The number of blood
transfusions given was significantly lower in the erythropoietin group,
with a mean of 0.3 (range 0–6) units compared to 1.6 (0–9) units in
the control group (
p
< 0.05). In conclusion, the
hemoglobin concentration at the time of surgery and during the week
following surgery was significantly higher in the group of patients
receiving r-HuEPO perioperatively compared to the placebo group
together with a significant lower use of blood transfusions in the
r-HuEPO group. However, the clinical implications of these findings has
yet to be proven.RID=" ID=" <E5>Correspondence to:</E5> N. Qvist, M.D., D.Sci. 相似文献
110.
Bokvist K Hoy M Buschard K Holst JJ Thomsen MK Gromada J 《European journal of pharmacology》1999,386(1):105-111
The effects of the two prandial glucose regulators, repaglinide and nateglinide, on ATP-sensitive K(+) (K(ATP)) channel activity, membrane potential and exocytosis in single rat pancreatic A-cells were investigated using the patch-clamp technique. K(ATP) channel activity was reversibly blocked by repaglinide (K(d)=22 nM) and nateglinide (K(d)=410 nM) and this was associated with membrane depolarisation and initiation of electrical activity. The effect of repaglinide and nateglinide on stimulation of glucagon secretion by direct interference with the exocytotic machinery was investigated by the use of capacitance measurements. Nateglinide, but not repaglinide, at concentrations similar to those required to block K(ATP) channels potentiated Ca(2+)-evoked exocytosis 3-fold. In alphaTC1-9 glucagonoma cells addition of nateglinide, but not repaglinide, was associated with stimulation of glucagon secretion. These results indicate that the fast-acting insulin secretagogue nateglinide is glucagonotropic primarily by stimulating Ca(2+)-dependent exocytosis. 相似文献